Please assess the completion status of the following clinical trial:

Trial Title: The Oslo Study of Clonidine in Elderly Patients With Delirium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient \> 65 years old admitted to the Medical department~* Delirium or subsyndromal delirium diagnosed within the last 48 hours~* Signed informed consent from patient or relatives~* Expected cooperation of the patients for the treatment and follow up~Exclusion Criteria:~* Symptomatic bradycardia, bradycardia due to sick-sinus-syndrome, second- or third- degree AV-block (not treated With pacemaker) or any other reason causing HR \<50 bpm at time of inclusion~* Symptomatic hypotension or orthostatic hypotension, or a systolic BP \<120 at the time of inclusion~* Ischemic stroke within the last 3 months or critical peripheral ischemia~* Acute coronary syndrome, unstable or severe coronary heart disease (symptoms at minimal physical activity; NYHA 3 and 4) and moderate to severe heart failure (NYHA 3 and 4).~* A diagnosis of polyneuropathy or pheochromocytoma~* Renal insufficiency (estimated GFR\<30 ml/min according to the MDRD formula).~* Body weight \< 45 kg.~* Considered as moribund on admission.~* Not able to take oral medications~* Current use of tricyclic antidepressants, monoamine reuptake inhibitors or ciclosporin~* Previously included in this study~* Adverse reactions to clonidine or excipients (lactose, saccharose)~* Not speaking or reading Norwegian~* Any other condition as evaluated by the treating physician~* Admitted to the ICU

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clonidine (Type: EXPERIMENTAL): Clonidine administered orally:~Day 1/loading doses: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days.
- Placebo (sugar pill) (Type: PLACEBO_COMPARATOR): Placebo administered orally (identical capsula as for expirimental drug):~Day 1/loading doases: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).